Drug Trial Radar · NCT05823246
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
Last checked: Nov 19, 2026Latest source record: May 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
66
Planned (sponsor's estimate)
Start
Apr 24, 2023
Primary completion
Oct 2023
Study completion Jul 2024
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.
Conditions
- Melanoma
- Urothelial Carcinoma
Interventions
QLF31907Drug
Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- (part 1)Dose-limiting toxicity(DLT)Time frame: 28days
- (part 2) Objective response rate(ORR)Time frame: up to 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
West China Hospital
Chengdu, Sichuan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.